SCHEMBL27118917

SCHEMBL27118917

COc1cc(N)c(C#N)cc1I

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 1/20 0.49
USP2 O75604 1/20 0.49
HTR1A P08908 2/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HTR2B P41595 2/20 0.38
CYP3A4 P08684 2/20 0.38
TSHR P16473 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPKAPK2 P49137 1/20 0.38
NPC1 O15118 1/20 0.37
IMPDH2 P12268 1/20 0.37
IMPDH1 P20839 1/20 0.37
PMP22 Q01453 2/20 0.37
XDH P47989 1/20 0.37
LMNA P02545 1/20 0.37
AR P10275 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1980619 0.85 ALDH1A1 (0.53) ALDH1A1KDM4EUSP2NPC1IMPDH2
SCHEMBL82833 0.84 ALDH1A1 (0.55) ALDH1A1KDM4EUSP2CYP3A4TSHR
SCHEMBL11153594 0.78 NPC1 (0.60) ALDH1A1KDM4EUSP2NPC1IMPDH2
SCHEMBL13720176 0.78 KDM4E (0.49) ALDH1A1KDM4EUSP2CYP3A4CYP1A2
SCHEMBL1708651 0.78 KDM4E (0.49) ALDH1A1KDM4EUSP2HTR2AHTR2C
SCHEMBL16290988 0.78 KDM4E (0.41) ALDH1A1KDM4EUSP2HTR1AHTR2A
SCHEMBL21996461 0.78 ALDH1A1 (0.49) ALDH1A1KDM4EUSP2HTR2ACYP3A4
SCHEMBL1511834 0.76 ALDH1A1 (0.60) ALDH1A1KDM4EUSP2NPC1IMPDH2
SCHEMBL13811603 0.76 ALDH1A1 (0.50) ALDH1A1KDM4EUSP2HTR2AIMPDH2
SCHEMBL5038230 0.76 NPC1 (0.45) ALDH1A1KDM4EHTR1AHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025227032-A1 METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES REMIX THERAPEUTICS INC. (US) 2025-10-30 WO disclosed
CN-115232108-B SOS1 degradation agent and preparation method and application thereof 领泰生物医药(绍兴)有限公司 2025-04-18 CN disclosed
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 US disclosed
US-20240261418-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 US disclosed
CN-117736222-A MTA synergistic PRMT5 inhibitor compounds having tricyclic or tetracyclic ring structures 烨辉医药科技(上海)有限公司 2024-03-22 CN disclosed
EP-4328219-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-02-28 EP disclosed
EP-4328219-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-02-28 EP disclosed
CN-115232114-B SOS1 degradation agent and preparation method and application thereof 上海领泰生物医药科技有限公司 2023-12-19 CN disclosed
WO-2022223039-A1 SOS1 DEGRADER, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海领泰生物医药科技有限公司 2022-10-27 WO disclosed
WO-2022223033-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海领泰生物医药科技有限公司 2022-10-27 WO disclosed
WO-2022223034-A1 SOS1 DEGRADATION AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海领泰生物医药科技有限公司 2022-10-27 WO disclosed
CN-115232111-A SOS1 degradation agent and preparation method and application thereof 上海领泰生物医药科技有限公司 2022-10-25 CN disclosed
CN-115232114-A SOS1 degradation agent and preparation method and application thereof 上海领泰生物医药科技有限公司 2022-10-25 CN disclosed
CN-115232108-A SOS1 degradation agent and preparation method and application thereof 上海领泰生物医药科技有限公司 2022-10-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240261418-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SOS1, RAC1, RSU1 ALDH1A1 1691/4885KDM4E 3321/4885USP2 176/4885
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF RAC1, SOS1, RSU1 ALDH1A1 1571/4885KDM4E 3661/4885USP2 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.